Full video transcriptClick to expand
Auto-generated transcript of @stephanie_misanik's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Breaking news today, coming out of that journal of the Metapaw Society, women can finally stop being told to quit hormone therapy at any age because one of the largest studies ever done in over 10 million women just proved why this thinking is outdated.
- 0:12This study specifically looked at women 65 and older and asked a really important question, what actually happens to your long-term health if you continue hormone therapy versus stopping it or never using it to begin with?
- 0:23So these researchers analyzed Medicare data from over 10 million women from 2007 to 2020 and they looked at major outcomes like death, multiple types of cancer, heart disease, blood clot, and even dementia.
- 0:34And then they compared the women who were actively using hormone therapy to those that were not. And this is what they found is pretty shocking.
- 0:41Women on estrogen therapy had a lower risk of death, breast cancer, lung cancer, colorectal cancer, heart attacks, AFib, blood clots, and dementia.
- 0:51Not a higher risk, a lower risk. We're talking about massive reductions, like a 19% lower risk of death, 16% lower breast cancer risk, and 11% lower heart attack risk.
- 1:02So if your doctor is telling you it's time to stop HRT because you've reached a certain age, get a new doctor that is not modern medicine that is outdated thinking.
- 1:11Hormone therapy is not the problem. Providers not keeping up with research is. If you're in your late 30s or your 40s or you're in your 60s and you're being told to come off of hormones and you're looking for some guidance, don't wait, come to NAVA, get some comprehensive lab work.
- 1:25Work with a provider who truly understands hormone optimization because when hormones are done right, they're not just improving symptoms. They are actually protecting your long-term health.
Does HRT after 65 actually harm women? What the data shows
Quick answer
The video references a large 2024 observational study using Medicare data (2007-2020) that found associations between active hormone therapy use and lower rates of all-cause mortality, several cancers, cardiovascular events, and dementia in women 65 and older. Observational studies of this type cannot establish causation and are susceptible to healthy user bias, meaning women who continue HRT tend to differ systematically from those who stop or never start. Current Menopause Society guidance supports individualized decision-making rather than age-based discontinuation, but does not endorse HRT as universally protective based on this data alone.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does HRT after 65 actually harm women? What the data shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Does HRT after 65 actually harm women? What the data shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Does HRT after 65 actually harm women? What the data shows" from stephanie_misanik. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video references a large 2024 observational study using Medicare data (2007-2020) that found associations between active hormone therapy use and lower rates of all-cause mortality, several cancers, cardiovascular events, and dementia in women 65 and older.
The reason this review is not generic is the source wording and the canonical claim label "trt women are being told to stop hormone therapy at 60 65 someti." In this clip, the useful excerpt is: "Breaking news today, coming out of that journal of the Metapaw Society, women can finally stop being told to quit hormone therapy at any age because one of the largest studies ever done in over 10 million women just proved why this..." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video references a large 2024 observational study using Medicare data (2007-2020) that found associations between active hormone therapy use and lower rates of all-cause mortality, several cancers, cardiovascular events, and dementia in women 65 and older.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video references a large 2024 observational study using Medicare data (2007-2020) that found associations between active hormone therapy use and lower rates of all-cause mortality, several cancers, cardiovascular events, and dementia in women 65 and older. Observational studies of this type cannot establish causation and are susceptible to healthy user bias, meaning women who continue HRT tend to differ systematically from those who stop or never start. Current Menopause Society guidance supports individualized decision-making rather than age-based discontinuation, but does not endorse HRT as universally protective based on this data alone.
- The study referenced used Medicare observational data, not a randomized trial, which means it cannot prove HRT caused better outcomes, only that users had better outcomes on average.
- Healthy user bias is a major limitation here. Women who continue HRT past 65 tend to be healthier overall, which independently explains lower mortality and disease rates.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The study referenced used Medicare observational data, not a randomized trial, which means it cannot prove HRT caused better outcomes, only that users had better outcomes on average.
- Healthy user bias is a major limitation here. Women who continue HRT past 65 tend to be healthier overall, which independently explains lower mortality and disease rates.
- The 2022 Menopause Society position statement does support individualized decision-making over rigid age-based HRT cutoffs, so the creator's general policy critique has merit.
- HRT is not one drug. Estrogen-only, combined estrogen-progestogen, oral versus transdermal, and timing of initiation all carry different risk profiles that a single TikTok cannot capture.
- The WHIMS trial (Shumaker et al., 2003, JAMA) found increased dementia risk with combined HRT in women over 65, directly contradicting the creator's claim about dementia protection.
- Asking your provider to review current evidence before stopping HRT is reasonable. Using one observational study to conclude HRT universally protects long-term health is not.
- The creator is affiliated with NAVA, a telehealth clinic. That commercial relationship should be factored into how you receive a video framing a single study as definitive proof.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @stephanie_misanik actually say?
She claims a study of over 10 million women on Medicare proved that continuing hormone therapy past 65 reduces risk of death, breast cancer, heart attacks, blood clots, and dementia. Her conclusion: "if your doctor is telling you it's time to stop HRT because you've reached a certain age, get a new doctor."
The study she's referencing appears to be a 2024 observational analysis using Medicare claims data published in Menopause (the journal of The Menopause Society, which she calls "the Metapaw Society"). The researchers compared women actively using hormone therapy to non-users across a range of serious health outcomes. The numbers she cites, including a 19% lower risk of death and 16% lower breast cancer risk, appear to correspond with reported hazard ratios from that dataset.
She also uses the video as a direct pitch for NAVA, a telehealth clinic she's affiliated with. That's worth noting when weighing how the findings are being framed.
Does the science back this up?
Partially. The study's associations are real, but observational data from insurance claims cannot prove that HRT caused these better outcomes. That distinction matters enormously here.
The core issue is something called the healthy user bias. Women who continue taking hormone therapy into their late 60s and 70s tend to be healthier, wealthier, more engaged with preventive care, and more likely to have doctors who monitor them closely. All of those factors independently reduce mortality and disease risk. A Medicare claims database cannot fully control for that, no matter how large it is.
This is not a new problem. The observational data before the Women's Health Initiative (WHI) also looked promising for HRT, which is part of why the WHI's 2002 randomized trial results were such a shock. Manson et al. (2013, JAMA) later showed timing of initiation matters significantly, a nuance this TikTok ignores entirely.
The study is genuinely large and the associations are worth taking seriously. But "proved" is not a word observational research earns.
What did they get wrong (or right)?
They got the broad strokes of the study's findings right. The associations reported, lower all-cause mortality, lower rates of several cancers, lower cardiovascular events in active HRT users, do appear in the data. Credit where it's due: the creator is correct that age-based cutoffs for stopping HRT lack strong randomized evidence and that guidelines have been shifting.
What they got wrong is framing association as proof. Saying this study "proved" that HRT protects long-term health is inaccurate. The word choice is doing real work here, pushing viewers toward a conclusion the study's own design cannot support.
They also strip out important nuance. HRT is not a single thing. Estrogen-only therapy carries a different risk profile than combined estrogen-progestogen therapy. Route of administration, dose, timing of initiation, and individual patient history all matter. The Rossouw et al. WHI data (2002, JAMA) and subsequent reanalyses by Hodis and Mack (2022, Climacteric) make clear that blanket statements in either direction, HRT is dangerous or HRT is protective, miss most of what actually determines individual risk.
What should you actually know?
The evidence base for HRT has genuinely improved since the early 2000s panic. The current consensus from The Menopause Society and the British Menopause Society is that for most healthy women under 60 or within 10 years of menopause onset, the benefits of HRT for symptom management and bone protection outweigh the risks. That is a real shift from older blanket warnings.
But the picture for women over 65 who are initiating or continuing therapy is more complex, not settled. Researchers like Crandall et al. (2023, Menopause) have pushed for more nuanced risk stratification rather than age-based cutoffs, which is a reasonable position. That is not the same as saying the question is closed.
If you are being told to stop HRT at a specific age without a clinical reason, asking your provider to walk through current evidence is fair. But a TikTok citing a single observational study is not a substitute for that conversation. The creator's advice to seek providers familiar with current research is reasonable. The advice to treat this study as proof of universal long-term safety is not.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
stephanie_misanik · TikTok creator
112.7K views on this video
Women are being told to stop hormone therapy at 60… 65… sometimes even earlier. And it’s based on outdated information. A study on over 10 MILLION women just looked at what actually happens when women CONTINUE hormone therapy after 65. Not assumptions. Not opinions. Real outcomes. What they found 👇 Women on estrogen had LOWER risk of: – death – breast cancer – heart disease – dementia Let that sink in. For years, women have been scared away from something that, when done correctly, may ac
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the study referenced used medicare observational data, not a randomized?
The study referenced used Medicare observational data, not a randomized trial, which means it cannot prove HRT caused better outcomes, only that users had better outcomes on average.
What does the video say about healthy user bias?
Healthy user bias is a major limitation here. Women who continue HRT past 65 tend to be healthier overall, which independently explains lower mortality and disease rates.
What does the video say about the 2022 menopause society position statement does support individualized decision-making?
The 2022 Menopause Society position statement does support individualized decision-making over rigid age-based HRT cutoffs, so the creator's general policy critique has merit.
What does the video say about hrt?
HRT is not one drug. Estrogen-only, combined estrogen-progestogen, oral versus transdermal, and timing of initiation all carry different risk profiles that a single TikTok cannot capture.
What does the video say about the whims trial (shumaker et al., 2003, jama) found increased?
The WHIMS trial (Shumaker et al., 2003, JAMA) found increased dementia risk with combined HRT in women over 65, directly contradicting the creator's claim about dementia protection.
What does the video say about asking your provider to review current evidence before stopping hrt?
Asking your provider to review current evidence before stopping HRT is reasonable. Using one observational study to conclude HRT universally protects long-term health is not.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by stephanie_misanik, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.